Fate Therapeutics (FATE) Rating Reiterated by Wells Fargo & Co

Wells Fargo & Co reissued their outperform rating on shares of Fate Therapeutics (NASDAQ:FATE) in a research report released on Tuesday. The brokerage currently has a $19.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $10.00.

Several other analysts also recently weighed in on the company. Zacks Investment Research upgraded Fate Therapeutics from a hold rating to a buy rating and set a $7.50 target price for the company in a research note on Tuesday, January 9th. Wedbush restated an outperform rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Monday, December 18th. Piper Jaffray Companies initiated coverage on Fate Therapeutics in a research note on Monday, December 18th. They set an overweight rating and a $10.00 target price for the company. HC Wainwright restated a buy rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Wednesday, December 13th. Finally, Raymond James Financial restated a buy rating on shares of Fate Therapeutics in a research note on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $13.00.

How to Become a New Pot Stock Millionaire

Shares of Fate Therapeutics (NASDAQ:FATE) opened at $13.17 on Tuesday. Fate Therapeutics has a 52 week low of $2.52 and a 52 week high of $14.45. The firm has a market capitalization of $671.43, a P/E ratio of -12.91 and a beta of 1.65. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.21 and a current ratio of 9.29.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. The business’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts forecast that Fate Therapeutics will post -0.91 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in FATE. Schwab Charles Investment Management Inc. bought a new stake in shares of Fate Therapeutics in the 2nd quarter worth approximately $214,000. Teachers Advisors LLC bought a new stake in shares of Fate Therapeutics in the 2nd quarter worth approximately $233,000. TIAA CREF Investment Management LLC bought a new stake in shares of Fate Therapeutics in the 2nd quarter worth approximately $373,000. New York State Common Retirement Fund bought a new stake in shares of Fate Therapeutics in the 2nd quarter worth approximately $131,000. Finally, Northern Trust Corp lifted its position in shares of Fate Therapeutics by 968.7% in the 2nd quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock worth $1,193,000 after acquiring an additional 333,753 shares during the period. Institutional investors own 68.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Fate Therapeutics (FATE) Rating Reiterated by Wells Fargo & Co” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://sportsperspectives.com/2018/03/10/fate-therapeutics-fate-rating-reiterated-by-wells-fargo-co.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply